The answer to the right hon. Gentleman’s question is both. There are issues with how NICE assesses new drugs, particularly cutting-edge drugs such as Kadcyla. He will know, because of his involvement in the last Government, that they established the cancer drugs fund. It is not an either/or, but something we all need to come together to discuss, and that people with more scientific knowledge than me might wish to consider.
Breast Cancer Drugs
Proceeding contribution from
Siobhain McDonagh
(Labour)
in the House of Commons on Thursday, 26 January 2017.
It occurred during Backbench debate on Breast Cancer Drugs.
Type
Proceeding contribution
Reference
620 c504
Session
2016-17
Chamber / Committee
House of Commons chamber
Librarians' tools
Timestamp
2024-08-13 12:55:27 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000334
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000334
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000334